FDA Proposes PDUFA VIII Commitment Letter for FY 2028–2032
Pharmaceutical sponsors and legal counsel must track and comment on proposed PDUFA VIII changes by October 16, 2026, as the draft introduces new review timelines, meeting structures, and user fee provisions that will govern FDA interactions through 2032.
On August 14, 2026, the FDA published a proposed eighth commitment letter under the Prescription Drug User Fee Act, covering fiscal years 2028 through 2032. The draft, which replaces the expiring PDUFA VII framework, introduces new mechanisms to reduce complete response letters and missed goal dates, including a discretionary one-time goal date extension tied to pre-approval inspection responses and a formal process for prioritizing pivotal protocols. It expands multi-divisional meeting opportunities, creates new Chemistry, Manufacturing, and Controls (CMC) facility lifecycle engagement pathways, and transitions several regulatory science pilots—such as Model-Informed Drug Development and rare-disease endpoint advancement—into routine review practices. The proposal also teases structural user fee changes, including incentives for U.S.-based clinical trials and a new supplement fee for non-orphan indications, which will require subsequent legislation. A hybrid public meeting is scheduled for September 16, 2026, with written comments due October 16, 2026. In-house counsel for pharmaceutical and biotech companies should evaluate how these proposed changes affect development timelines, regulatory strategy, and fee budgeting, and consider whether to participate in the comment process.